September 18, 2017 — Corindus Vascular Robotics Inc. announced first patient enrollment in the PRECISION GRX Registry, a post-market study to continue market surveillance of the company's second-generation CorPath GRX System.

Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating the efficacy of Philips Spectranetics' Stellarex .035-inch drug-coated balloon (DCB) for peripheral arterial disease (PAD) in comparison to uncoated balloon angioplasty. Marianne Brodmann, M.D., of the Medical University of Graz in Austria, presented the data as a late-breaking trial at the Vascular Interventional Advances (VIVA 17) Annual Conference, Sept. 11-14 in Las Vegas.

September 18, 2017 – Claret Medical announced publication of a new study in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions that underscores the role of the Sentinel Cerebral Protection System (CPS) in significantly reducing the early occurrence of stroke associated with

Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its QMAPP hemodynamic monitoring system.

Hitachi Healthcare Americas Inc. announced it has attained U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Supria True64 computed tomography (CT) system.

September 15, 2017 — Philips highlighted its newest solution for nuclear cardiology, CardioMD IV, at the American Society of Nuclear Cardiology’s Annual Scientific Session, Sept. 14-17 in Kansas City, Mo.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now